Malignant hyperthermia

Research output: Contribution to journalArticle

Abstract

The work of MHAUS has increased awareness of this rare condition. The development of safe alternative anesthetic drugs, improved monitoring and effective treatment have lowered the mortality of MH to almost zero. The key to success is early diagnosis and use of dantrolene to abort the attack. Future research will improve genotyping and help elucidate the molecular mechanism of excitation-contraction coupling in skeletal muscle. This will have implications in many other areas of physiology and pharmacology. Improvements in the CHCT and refinement of a variety of alternative tests may eliminate the false positives and negatives that confound phenotyping. Recent reports of fatalities from MH arising in the 'office' environment, coupled with the increasing popularity of this mode of surgical treatment should remind us that MH is still a serious disease. We should not become complacent and allow our high standards of monitoring and awareness of MH to lapse. The availability of dantrolene in all anesthetizing locations in an issue that has yet to be addressed.

Original languageEnglish (US)
Pages (from-to)299-309
Number of pages11
JournalProgress in Anesthesiology
Volume13
Issue number16
StatePublished - 1999

Fingerprint

Dantrolene
Malignant Hyperthermia
Excitation Contraction Coupling
Drug Monitoring
Anesthetics
Early Diagnosis
Skeletal Muscle
Pharmacology
Mortality

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Malignant hyperthermia. / Pennant, J. H.

In: Progress in Anesthesiology, Vol. 13, No. 16, 1999, p. 299-309.

Research output: Contribution to journalArticle

Pennant, JH 1999, 'Malignant hyperthermia', Progress in Anesthesiology, vol. 13, no. 16, pp. 299-309.
Pennant, J. H. / Malignant hyperthermia. In: Progress in Anesthesiology. 1999 ; Vol. 13, No. 16. pp. 299-309.
@article{2f11d52316d34269bf3afdb017f2263a,
title = "Malignant hyperthermia",
abstract = "The work of MHAUS has increased awareness of this rare condition. The development of safe alternative anesthetic drugs, improved monitoring and effective treatment have lowered the mortality of MH to almost zero. The key to success is early diagnosis and use of dantrolene to abort the attack. Future research will improve genotyping and help elucidate the molecular mechanism of excitation-contraction coupling in skeletal muscle. This will have implications in many other areas of physiology and pharmacology. Improvements in the CHCT and refinement of a variety of alternative tests may eliminate the false positives and negatives that confound phenotyping. Recent reports of fatalities from MH arising in the 'office' environment, coupled with the increasing popularity of this mode of surgical treatment should remind us that MH is still a serious disease. We should not become complacent and allow our high standards of monitoring and awareness of MH to lapse. The availability of dantrolene in all anesthetizing locations in an issue that has yet to be addressed.",
author = "Pennant, {J. H.}",
year = "1999",
language = "English (US)",
volume = "13",
pages = "299--309",
journal = "Progress in Anesthesiology",
issn = "0891-5784",
publisher = "Dannemiller Memorial Educational Foundation",
number = "16",

}

TY - JOUR

T1 - Malignant hyperthermia

AU - Pennant, J. H.

PY - 1999

Y1 - 1999

N2 - The work of MHAUS has increased awareness of this rare condition. The development of safe alternative anesthetic drugs, improved monitoring and effective treatment have lowered the mortality of MH to almost zero. The key to success is early diagnosis and use of dantrolene to abort the attack. Future research will improve genotyping and help elucidate the molecular mechanism of excitation-contraction coupling in skeletal muscle. This will have implications in many other areas of physiology and pharmacology. Improvements in the CHCT and refinement of a variety of alternative tests may eliminate the false positives and negatives that confound phenotyping. Recent reports of fatalities from MH arising in the 'office' environment, coupled with the increasing popularity of this mode of surgical treatment should remind us that MH is still a serious disease. We should not become complacent and allow our high standards of monitoring and awareness of MH to lapse. The availability of dantrolene in all anesthetizing locations in an issue that has yet to be addressed.

AB - The work of MHAUS has increased awareness of this rare condition. The development of safe alternative anesthetic drugs, improved monitoring and effective treatment have lowered the mortality of MH to almost zero. The key to success is early diagnosis and use of dantrolene to abort the attack. Future research will improve genotyping and help elucidate the molecular mechanism of excitation-contraction coupling in skeletal muscle. This will have implications in many other areas of physiology and pharmacology. Improvements in the CHCT and refinement of a variety of alternative tests may eliminate the false positives and negatives that confound phenotyping. Recent reports of fatalities from MH arising in the 'office' environment, coupled with the increasing popularity of this mode of surgical treatment should remind us that MH is still a serious disease. We should not become complacent and allow our high standards of monitoring and awareness of MH to lapse. The availability of dantrolene in all anesthetizing locations in an issue that has yet to be addressed.

UR - http://www.scopus.com/inward/record.url?scp=0032793049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032793049&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 299

EP - 309

JO - Progress in Anesthesiology

JF - Progress in Anesthesiology

SN - 0891-5784

IS - 16

ER -